Breast cancer, version 3.2018 featured updates to the NCCN guidelines

Matthew P. Goetz, William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, William B. Farrar, Sharon H. Giordano, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O’ReganSameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Melinda L. Telli, John H. Ward, Jessica S. Young, Dorothy A. Shead, Rashmi Kumar

Research output: Contribution to journalArticlepeer-review

157 Scopus citations

Abstract

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.

Original languageEnglish
Pages (from-to)118-126
Number of pages9
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume17
Issue number2
DOIs
StatePublished - Feb 2019

Fingerprint

Dive into the research topics of 'Breast cancer, version 3.2018 featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this